Watch out, Novartis: Eli Lilly, Boehringer Ingelheim notch broad heart failure OK for Jardiance
Eli Lilly and Boehringer Ingelheim just got the green light to go much deeper into the heart failure market with their SGLT2 inhibitor Jardiance.
The FDA has approved the drug as a treatment for a broad swath of patients to reduce their risk of cardiovascular death and hospitalization for heart failure regardless of ejection fraction.
While Jardiance was initially developed and approved for type 2 diabetes, Lilly and Boehringer have devised an extensive clinical trial program to test its potential in cardiovascular diseases. Just six months ago, it was approved for one type of heart failure — with reduced left ventricular ejection fraction (LVEF).
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.